FDA Weighs In on Actos Risks
The federal government’s Food and Drug Administration (FDA) recently announced that the public should be aware of the risks associated with extended use of Actos (pioglitazone). For thousands of American diabetes patients, Actos is an important pharmaceudical solution to their health problems. However, medical research cited by the FDA argues that Actos may do more harm than good.
An ongoing safety review suggests that increased risk of bladder cancer positively correlates with relatively large, cumulative exposure to pioglitazone. In short, beyond 12 months, Actos patients may see the early symptoms of bladder cancer.
Are you an Actos patient who has noticed unusual bladder-related symptoms like blood in your urine? If so, the time to act is now and the call to make is to the attorneys and dedicated professionals at Fears Nachawati. With years of experience, we can help you. For your free consultation, call us at 1.866.545.8364 or email email@example.com.